{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:52Z","timestamp":1793651092865,"version":"4.5.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["PI06\/0024"],"award-info":[{"award-number":["PI06\/0024"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PS09\/00748"],"award-info":[{"award-number":["PS09\/00748"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["PII2\/00060"],"award-info":[{"award-number":["PII2\/00060"]}]},{"name":"RETICS Program","award":["RD08\/0075"],"award-info":[{"award-number":["RD08\/0075"]}]},{"name":"RETICS Program","award":["RD12\/0009\/0013"],"award-info":[{"award-number":["RD12\/0009\/0013"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.semarthrit.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T17:16:51Z","timestamp":1457543811000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist"],"prefix":"10.1016","volume":"46","author":[{"given":"Christina","family":"Charles-Schoeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonzalez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Boy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.03.004_bib1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2006.059980","article-title":"Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?","volume":"67","author":"Gonzalez","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.22482","article-title":"HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis","volume":"57","author":"Gonzalez-Gay","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/BOR.0b013e32834ff2fd","article-title":"Risk factors for cardiovascular disease in rheumatoid arthritis","volume":"24","author":"Gabriel","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib5","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2013-203293","article-title":"Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions","volume":"73","author":"Johnsson","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2010.09.002","article-title":"2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"56","author":"Greenland","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib8","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib9","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib10","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report","volume":"106","author":"National Cholesterol Education Program Expert Panel","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MJT.0b013e31828b8463","article-title":"Systematic Review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?","volume":"22","author":"Bishop","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.atherosclerosis.2012.02.032","article-title":"Inflammation modulates human HDL composition and function in vivo","volume":"222","author":"de la Llera Moya","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2009.122374","article-title":"Total cholesterol and LDL levels decrease before rheumatoid arthritis","volume":"69","author":"Myasoedova","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-2143(98)90083-X","article-title":"Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response","volume":"131","author":"Akgun","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccc.2005.08.008","article-title":"Dyslipidemia in the critically ill","volume":"22","author":"Marik","year":"2006","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib17","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/01.CCM.0000171272.50888.AD","article-title":"Serum lipids and disease severity in children with severe meningococcal sepsis","volume":"33","author":"Vermont","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib19","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3899\/jrheum.130365","article-title":"Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study","volume":"40","author":"Ajeganova","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/ket333","article-title":"Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data","volume":"53","author":"Morgan","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.62.9.842","article-title":"Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis","volume":"62","author":"Boers","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib24","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar1952","article-title":"Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment\u2014a prospective, controlled study","volume":"8","author":"Georgiadis","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/acr.20393","article-title":"Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients","volume":"63","author":"Morris","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib28","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib29","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib30","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","article-title":"Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)","volume":"21","author":"Yamanaka","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","volume":"41","author":"van Sijl","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib37","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Daien","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/annrheumdis-2012-202089","article-title":"Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation","volume":"73","author":"Kirkham","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib39","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1136\/ard.2009.127597","article-title":"Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study","volume":"69","author":"Jamnitski","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib40","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib42","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib48","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib49","unstructured":"Pfizer Inc. Tofacitinib for the treatment of rheumatoid arthritis. NDA 203214. Briefing document. \u3008http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM302960.pdf\u3009; Accessed March 29, 2016."},{"issue":"1A","key":"10.1016\/j.semarthrit.2016.03.004_bib50","doi-asserted-by":"crossref","first-page":"48S","DOI":"10.1016\/S0002-9343(98)00212-5","article-title":"Epidemiologic aspects of lipid abnormalities","volume":"105","author":"Criqui","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib51","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Millan","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2016.03.004_bib52","first-page":"S30","article-title":"Low density lipoprotein (LDL c) exposure-response analysis for tofacitinib (CP-690,550) in patients with rheumatoid arthritis","volume":"91","author":"Riley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2016.03.004_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2014-eular.4361","article-title":"Association of mean changes in laboratory safety parameters with C-reactive protein at baseline and week 12 in rheumatoid arthritis patients treated with tofacitinib","volume":"73","author":"Strand","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologics and tofacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib56","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/art.37916","article-title":"Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial","volume":"65","author":"Navarro-Millan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib58","doi-asserted-by":"crossref","first-page":"e001826","DOI":"10.1161\/JAHA.112.001826","article-title":"Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion","volume":"1","author":"Turner","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib59","first-page":"78","article-title":"High density lipoprotein and it\u2032s dysfunction","volume":"6","author":"Eren","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib60","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/art.34363","article-title":"Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis","volume":"64","author":"Watanabe","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/annrheumdis-2012-202033","article-title":"High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis","volume":"72","author":"Vivekanandan-Giri","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib63","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00592-008-0066-3","article-title":"Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes","volume":"46","author":"Ikeda","year":"2009","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib65","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.38118","article-title":"Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis","volume":"65","author":"Charles-Schoeman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib66","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1136\/annrheumdis-2014-205543","article-title":"Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"73","author":"Lopez-Mejias","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib67","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/ard.2008.092171","article-title":"Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients","volume":"68","author":"Popa","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2016.03.004_bib68","first-page":"S626","article-title":"Anti-tumor necrosis factor a therapy (etanercept) plus methotrexate lowers serum amyloid a levels to a greater extent than triple oral disease modifying anti-rheumatic drug therapy in early rheumatoid arthritis subjects","volume":"65","author":"Metes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2016.03.004_bib69","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/annrheumdis-2013-eular.1264","article-title":"Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis","volume":"72","author":"McInnes","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib71","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib72","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar4271","article-title":"SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis","volume":"15","author":"Gomez-Vaquero","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib73","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/annrheumdis-2011-201209","article-title":"Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?","volume":"71","author":"Gonzalez-Gay","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib74","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/annrheumdis-2013-203688","article-title":"Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"72","author":"Corrales","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib75","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2012-203101","article-title":"Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study","volume":"73","author":"Corrales","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib76","first-page":"391","article-title":"No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000\u20132008","volume":"33","author":"Kerola","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib77","first-page":"382","article-title":"Effect of biologic disease modifiers on cardiovascular risk of patients with rheumatoid arthritis\u20142 years prospective cohort study [abstract]","volume":"65","author":"Khraishi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib78","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib79","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2016.03.004_bib80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2012-eular.2101","article-title":"Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral JAK inhibitor","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib81","author":"Charles-Schoeman","year":"2015","journal-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3899\/jrheum.121302","article-title":"Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study","volume":"40","author":"Akkara Veetil","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.004_bib83","unstructured":"Pfizer Inc. Xeljanz prescribing information. \u3008http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959\u3009; Accessed March 29, 2016."},{"key":"10.1016\/j.semarthrit.2016.03.004_bib84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:18:41Z","timestamp":1748801921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0049017216000949"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}